SCHEMBL556871

SCHEMBL556871

CC1CCCC(NC(=O)c2ccc(C3OCC4(CO3)COC(c3ccc(C(=O)NC5CCCC(C)C5C)cc3)OC4)cc2)C1C

nearest known ligand 0.56

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 3/20 0.56
NPC1 O15118 2/20 0.56
TAS1R3 Q7RTX0 7/20 0.50
TAS1R1 Q7RTX1 7/20 0.50
TAS1R2 Q8TE23 6/20 0.50
KMT2A Q03164 3/20 0.49
ATM Q13315 1/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
MLYCD O95822 1/20 0.46
ALDH1A1 P00352 3/20 0.46
LMNA P02545 1/20 0.46
HPGD P15428 1/20 0.46
TSHR P16473 1/20 0.46
KDM4E B2RXH2 1/20 0.46
GAA P10253 1/20 0.46
HSD17B10 Q99714 1/20 0.46
POLB P06746 1/20 0.46
MEN1 O00255 1/20 0.46
PKM P14618 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL517182 0.84 NPC1 (0.68) RAB9ANPC1TAS1R3TAS1R1TAS1R2
SCHEMBL517271 0.80 NPC1 (0.64) RAB9ANPC1TAS1R3TAS1R1TAS1R2
SCHEMBL517511 0.78 MAOA (0.57) RAB9ANPC1KMT2AALDH1A1LMNA
SCHEMBL14396737 0.78 RAB9A (0.61) RAB9ANPC1TAS1R3TAS1R1TAS1R2
SCHEMBL12858459 0.77 TAS1R3 (0.63) RAB9ANPC1TAS1R3TAS1R1TAS1R2
SCHEMBL12858441 0.76 NPC1 (0.58) RAB9ANPC1TAS1R3TAS1R1TAS1R2
SCHEMBL14252951 0.76 NPC1 (0.58) RAB9ANPC1TAS1R3TAS1R1TAS1R2
SCHEMBL2915377 0.75 TAS1R3 (0.66) RAB9ANPC1TAS1R3TAS1R1TAS1R2
SCHEMBL518128 0.75 RAB9A (0.68) RAB9ANPC1TAS1R3TAS1R1TAS1R2
SCHEMBL518121 0.74 NPC1 (0.43) RAB9ANPC1KMT2AMLYCDALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9023921-B2 Method for inhibiting crystal growth rate of amide compound and method for producing molded article of polyolefin-based resin NEW JAPAN CHEMICAL CO., LTD. (JP) 2015-05-05 US disclosed
EP-2431415-A1 METHOD FOR CONTROLLING CRYSTAL GROWTH RATE OF AMIDE COMPOUND AND METHOD FOR PRODUCING MOLDED ARTICLE OF POLYOLEFIN-BASED RESIN New Japan Chemical Co., Ltd. (JP) 2012-03-21 EP disclosed
US-20120035304-A1 METHOD FOR INHIBITING CRYSTAL GROWTH RATE OF AMIDE COMPOUND AND METHOD FOR PRODUCING MOLDED ARTICLE OF POLYOLEFIN-BASED RESIN NEW JAPAN CHEMICAL CO., LTD. (JP) 2012-02-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120035304-A1 METHOD FOR INHIBITING CRYSTAL GROWTH RATE OF AMIDE COMPOUND AND METHOD FOR PRODUCING MOLDED ARTICLE OF POLYOLEFIN-BASED RESIN MNAT1, RFT1, RTF1 RAB9A 4496/4885NPC1 2313/4885TAS1R3 1107/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.